Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
What's in store for Indian pharma? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 20, 2009

    What's in store for Indian pharma?

    The overall growth for the Indian pharma sector has been mixed in the last few quarters. While there were some factors that impacted the entire sector as a whole, there were certain developments which were company specific. Nevertheless they were instrumental in determining the performance of the companies. Many domestic pharma companies, especially the ones who had taken on foreign debt on their books, had a tough time in the last few quarters as the rupee depreciated sharply against the US dollar. This compelled them to report huge forex losses which dented profitability.

    Companies such as Ranbaxy and Sun Pharma ran into trouble with the US FDA as their manufacturing plants were found not to be complying with the quality standards of the US FDA. This adversely impacted their sales from the US. The global crisis also impacted the business of the pharma companies to a certain extent especially in the semi regulated markets of Russia and the CIS as the latter's currencies got significantly devalued. As a result many companies were compelled to focus more on receivables in these markets even if that meant foregoing some sales.

    The September quarter results season for the pharma sector will begin this week and they are expected to be much better than what was witnessed in the latter half of FY09. The magnitude of forex losses is not likely to be pronounced this quarter given that the Indian unit has appreciated against the US dollar. While most of the companies are likely to post decent revenues from the domestic market, the exports performance is expected to be a mixed bag. Revenues from the emerging markets are likely to grow at a robust pace but sales are likely to be relatively lower in the developed markets of US and Europe. For those plagued by US FDA issues, growth in sales from the US market is not likely to be much.

    MNC pharma companies are also expected to post better results as compared to what they did in the past two years. It must be noted that the performance of MNC pharma was hampered in FY09 due to trade issues, sale of non-core assets and rising input costs. But this scenario has changed as was evinced in the last two quarters and the top companies have begun to post decent growth in sales. Infact, dabbling in generics has emerged as an area of interest to these MNCs and some such as Pfizer India have already launched a couple of generic products in the domestic market to bolster performance.

    Having said that, looking at only quarterly numbers should not form the basis of investing in stocks, including those in the pharma sector. Infact, investment decisions have to be based from a 2-3 year perspective. In this regard, the long term prospects of the pharma sector look intact as the fundamentals in terms of governments across the world veering towards low cost generics have not changed. However, mirroring the Indian stockmarkets, pharma stocks have also rallied considerably over the past few months. Hence, we advice investors to adopt a stock specific approach while investing in the sector.



    Equitymaster requests your view! Post a comment on "What's in store for Indian pharma?". Click here!


    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    You've Heard of Timeless Books... Ever Heard of Timeless Stocks? (The 5 Minute Wrapup)

    Aug 19, 2017

    Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.

    Why NOW Is the WORST Time for Index Investing (The 5 Minute Wrapup)

    Aug 18, 2017

    Buying the index now will hardly help make money in stocks even in ten years.

    Trump Takes a Beating (Vivek Kaul's Diary)

    Aug 18, 2017

    Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.

    How To Read Your Mutual Fund Account Statement Correctly (Outside View)

    Aug 17, 2017

    PersonalFN simplifies the mutual fund account statement for you.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)